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progression is a150,000–350,000 for each therapy but glatiramer acetate (a651,796). 
Probabilistic sensitivity analysis conﬁrmed subcutaneous interferon beta-1a and inter-
feron beta-1b as the most cost-effective therapies (conﬁdence intervals remained below 
a45,000 per avoided relapse). Estimated budget impact of assuming 5–9% annual 
increase of subcutaneous interferon beta-1a market share equals 0.17–0.52% of actual 
RRMS cost in Spain. CONCLUSIONS: Subcutaneous interferon beta-1a is an efﬁcient 
strategy for RRMS in Spain as it allows an appropriate management and treatment 
of RRMS relapses and progression with a minor budgetary impact for SNHS.
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OBJECTIVES: Economic evaluation of Lacosamide (LCM) and standard treatment 
with commonly used antiepileptic drugs (ST) vs. ST alone in the Finnish setting. LCM 
is a new antiepileptic drug, indicated for adjunctive treatment of partial-onset seizures 
(POS) with or without secondary generalisation in patients aged 16 years and older. 
METHODS: A probabilistic decision tree based cost-effectiveness analysis (CEA) with 
second-order Monte Carlo simulation and a 2-year time-frame was performed in Excel 
from the Finnish societal perspective (productivity losses and VAT excluded). The 
efﬁcacy data were obtained from the LCM-trials, and the Finnish costs (inpatient, 
outpatient, GP, laboratory, drug) and utilities from published studies. Budget impact 
modelling (BIM) with a ﬁve year time-frame was done to assess the net monetary 
impact of LCM launch to the refractory epilepsy budget. Only drug costs were 
included in BIM. Conservatively, generic prices were used in all analyses. RESULTS: 
According to CEA, LCMST was associated with an incremental cost of a945 (mainly 
related to seizure management and drug acquisition), a gain of 0.040 QALYs and 8.92 
seizures avoided compared to ST alone. LCMST was associated with a cost of 
a23,396 per QALY gained and a106 per seizure avoided compared to ST alone. 
According to the cost-effectiveness acceptability frontier, the probability of LCM’s 
cost-effectiveness was 67.9% and 85.6% with a30,000 and a50,000 per QALY 
gained, respectively. The results were robust in sensitivity analyses. According to BIM, 
the expected annual budget increase due to launch of LCM is a0 in 2008, a7,653 in 
2009, a47,350 in 2010, a134,949 in 2011, and a232,609 in 2012. The relative 
increase in the annual epilepsy budget due to LCM is 0.08% in 2009, 0.46% in 2010, 
1.31% in 2011, and 2.23% in 2012. CONCLUSIONS: LCM is a valuable option for 
POS treatment because of its potential cost-effectiveness and low budget impact.
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OBJECTIVES: Neurostimulators (NS) for DBS are replaced when the battery goes to 
an end-of-life (EOL). Activa® RC, Medtronic’s new rechargeable NS, offers guaranteed 
9 years longevity. The objective was to perform a cost analysis of Activa® RC, vs. 
Kinetra® (previous non-rechargeable NS), based on the number of EOL replacements 
needed. METHODS: The following costs were included (hospital perspective, a, 
2009): 1) DBS acquisition costs; 2) surgical procedure cost: Spanish tariff for Parkin-
son disease surgery; 3) EOL NS’s replacement procedure cost: includes surgical pro-
cedure cost (excluding the acquisition costs of therapy components) and the NS cost. 
The EOL depends on patient energy requirements (disease-related) and on the NS: 
Kinetra®: dystonia patients replacements every 2 years; Parkinson disease, every 3–4 
years; essential tremor, every 4–5 years(expert opinion). Activa® RC: every 9 years for 
all indications. Cumulative costs/year was obtained for a 9-years timeframe to 
compare the costs and number of surgical replacements avoided with Activa® RC. The 
main cost driver, surgical procedure cost, was changed as a sensitivity analysis (SA). 
RESULTS: Thanks to higher battery longevity, the following savings could be 
obtained: 1) Dystonia patients, as higher energy requirement are needed, higher eco-
nomic beneﬁts are observed: at year a9, 57.585 saved/patient or 4 EOL-replacement 
avoided; 2) Parkinson disease, at year 9, 2 replacements are avoided, that represents 
a21.867 saved/patient; 3) Essential tremor, savings oscillates between a4.008-a21.867, 
avoiding 1–2 EOL-replacement in 9 years. CONCLUSIONS: Although initial acquisi-
tion costs of Activa® RC are higher, compared to Kinetra®, those are compensated 
after the ﬁrst Kinetra®’s EOL surgical replacement, obtaining important cost savings 
at year 9 (4.008a-57.585a/patient), avoiding 1–4 surgical replacements. The more 
energy requirements, the higher economic beneﬁts are observed with Activa® RC. An 
adequate patient selection is needed to maximize clinical and economic beneﬁts of 
Activa® RC-DBS.
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OBJECTIVES: Activa®, Medtronic’s DBS, is an effective,safe and reversible therapy 
for Parkinson disease, essential tremor and dystonia. A cost analysis was perform to 
estimate the economic beneﬁts related to 2 features of Activa PC® family, new DBS 
generation devices, and the net Budget impact (BI) for Spanish hospitals, compared 
to Kinetra®. METHODS: The 2 features: neurostimulator’s (NE) lower size and new 
stretchable extensions; both can avoid some adverse events (AEs) associated with 
Kinetra (no other beneﬁts were considered). A literature search was done to retrieve 
safety studies. Selection criteria: AEs related with NE &/or the extension, their inci-
dence and detailed treatment description. Health resource use was assigned to AEs 
treatment (Spanish hospital costs, Euros 2009): regional tariffs; acquisition costs. A 
net cost for each AEs was obtained, multiplying each AEs treatment incidence by its 
total cost. Total cost obtained with Activa PC®, compared to Kinetra®, corresponds 
to savings/patient. The net BI for Spanish hospitals was calculated: total incremental 
cost/Activa PC® treated patient instead of Kinetra® (considering AEs avoided and its 
savings). An AE incidence comparison was made as a sensitivity analysis (SA). 
RESULTS: 2 safety studies were selected. The 2 features could avoid 6 AEs, 2 related 
to NEs (hematoma in the NE implant site; infection/erosion); 4 with the extension 
(lead broke after a fall; extension fracture; skin ulceration in the connector; local dis-
comfort). In total, avoiding these AEs involved 591a saved/patient treated with Activa 
PC® family (SA obtained similar data). Including Activa PC® instead of Kinetra family 
in Spanish Hospitals involved a net BI per patient of a1.781. CONCLUSIONS: The 
new Activa PC family may avoid AEs related to the previous generation, Kinetra, with 
a decrease in the total cost per patient. The substitution of Kinetra® for Activa PC® 
family involves a small net budget impact per patient.
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OBJECTIVES: To examine the economic burden of newly diagnosed multiple sclerosis 
(MS) on the US health care system using a large, managed care database. METHODS: 
This was a retrospective cohort analysis of a large, US claims database. Cases were 
deﬁned as having either an MS diagnosis (ICD-9-CM 340) on at least 2 claims or 1 
prescription for MS treatment (glatiramer acetate, interferon betas, or natalizumab) 
between 2004 and 2006. The index date was the ﬁrst qualifying diagnosis or prescrip-
tion. We excluded patients with an MS diagnosis or treatment over the 12 month 
pre-index period, or without continuous enrollment from 12 months pre- to 12 
months post-index date. Each case had 5 controls without MS diagnoses or treatment 
matched on geographic region, insurance type, gender, relation to employee, age and 
lack of comorbid conditions with a similar period of continuous enrollment. Use of 
services was compared using chi-square tests, and 2008 adjusted costs were compared 
using the Wilcoxon rank-sum nonparametric tests. RESULTS: There were 1412 cases 
and 7,060 matched controls in the study. Sixty-six percent of the study population 
was female. MS patients were twice as likely to have emergency department (ED) visits 
(25.5% vs. 12.2%), 1.3 times as likely to have physician ofﬁce visits (95.8% vs. 
75.1%), and 2.4 times as likely to have used physical therapy (all p-values 0.001) 
services over the follow-up period. MS patients also had higher costs related to these 
services ($380 vs. $166, $614 vs. $228, and $268 vs. $74, respectively; all p-values 
0.001). Total costs for MS patients were signiﬁcantly higher than for controls 
($16,984 vs. $3,639 p  0.001). CONCLUSIONS: Newly diagnosed MS patients 
present a large burden on the health care system with additional 1st-year cost of over 
$13,000. While MS treatment drugs are expensive, this represents only one-third of 
the additional cost of care within the 1st year.
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OBJECTIVES: Migraine is prevalent, and headache-related disability can impact the 
ability of migraineurs to work and perform daily activities. This study examined the 
impact of CM compared to EM on work patterns and productivity across countries. 
METHODS: Web-based survey data were collected from migraineurs in the US, 
Canada, Germany, UK, France, Italy, Spain, Australia, and Taiwan. According to 
ICHD-2 criteria, presence of migraine (past 3-months headaches with pain, nausea, 
and photophobia/phonophobia) and q15 headache days/month indicated CM, and 
14 headache days/month indicated EM. Questions on absenteeism and presenteeism 
(reduced efﬁciency) in the preceding 4 weeks assessed headache impact on work or 
school. Linear and logistic regressions, as appropriate, compared migraine group and 
adjusted for age, gender, race, education, comorbidities, and country. RESULTS: Of 
63,001 invitees, 20,987 responded. A total of 9,118 completers (14.5%) comprised 
the ﬁnal cohort [n  516 (Australia) to 1597 (US)]; 83.6% female; 5.5% CM, 90.2% 
EM. CM respondents were 1.4 times more likely than EM to report that they had 
missed any work/school due to headache (95% CI  1.1, 1.8). CM reported missing 
a higher number of work/school days due to headache symptoms than EM (adjusted 
mean o SE  8.83 o 0.59 vs. 4.05 o 0.44, p  0.0001), as well as working more days 
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with headache symptoms (16.97 o 0.54 vs. 5.38 o 0.39, p  0.0001). CM also missed 
more days due to illnesses other than headache than EM participants (13.66 o 1.98 
vs. 9.33 o 1.42, p  0.01). CM and EM reported working at about half of their full 
effectiveness with headache symptoms (p  0.05). CM reported experiencing more 
impairment on work ability or activity than EM (CM  31.1%, EM  24.4%), or 
requiring more bed rest (CM  33.5%, EM  26.2%) when experiencing severe 
headaches. CONCLUSIONS: Migraine adversely affected presenteeism and increased 
absenteeism of migraine sufferers, particularly among those with CM, who missed 
more days and worked more days with headache than EM.
PND14
COSTS OF ILLNESS IN PARKINSON’S DISEASE IN SIX EUROPEAN 
COUNTRIES
von Campenhausen S, Winter Y, Reese JP, Dodel R
Philipps-University, Marburg, Germany
OBJECTIVES: To evaluate the direct and indirect costs of Parkinson´s Disease (PD) 
in a survey of ﬁve European countries and Russia. So far, cost-of-illness (COI) studies 
on PD have been conducted in some European countries only, none in Austria, Czech 
Republic, Portugal and Russia. The prevalence of PD in Europe varies between 115 
and 221 per 100,000, due to aging of population the number of persons affected is 
expected to double within the next 25 years. METHODS: Between 2003—2005 about 
100 patients of PD were recruited per study center. Clinical status (Hoehn & Yahr 
stage, Uniﬁed Parkinson’s Disease Rating Scale) was evaluated. Economic data were 
collected over a 6 months period using the “bottom-up” approach. Indirect costs were 
calculated by the human capital approach. Informal care was monetary valued. 
RESULTS: The total mean costs per patient ranged from a2620 to a9812 for the 6-
months observation period. Direct costs made about 60% to 70%, indirect costs made 
30% to 40% of total costs. Forty-seven percent to 92% of direct costs were on the 
account of the national health insurance systems. Patients’ co-payments constituted 
up to 14% of direct costs. Informal care generally was the prevalent form of care for 
PD patients. In half of the participating countries it was the major source of expendi-
ture. CONCLUSIONS: This is the ﬁrst observational study on the burden of PD across 
European countries and Russia. Costs of PD across Europe vary considerably. Reasons 
are multiple; differences in prices, health systems and traditions are some. PD repre-
sents a major burden on the individual, family, health services and society in Europe, 
especially in Eastern European countries. A major cost factor is the cost for care, which 
has enormous importance due to demographic development and extension of life 
expectancy.
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OBJECTIVES: To examine the economic impact of generic substitution of the anti-
epileptic drug (AED) Topiramate in Canada; and convert observed Canadian costs 
into the settings of France, Germany, Italy and the UK (UK). METHODS: Retrospec-
tive health claims from Québec’s provincial health plan (RAMQ) between January 
2006 and September 2008, and IMS Health data on European AED sales between 
1998 and 2008 were used. Patients with epilepsy (ICD-9: 345, 780.3, 780.39) and q2 
topiramate dispensings were selected. Patient-level health care utilization costs in 
Canada were calculated during mutually-exclusive periods of brand versus generic use 
of topiramate. Annualized Canadian health care costs were projected in each country 
(a2007/person-year) using Canadian rates, European prices and service-use ratios. 
Using market-level sales, topiramate utilization were forecasted for 12 months follow-
ing expected generic entry (September 2009-September 2010) using autoregressive and 
panel-data regression models. The impact of generic entry was projected for each 
country, stratiﬁed into its effect on market size, topiramate costs, and other health 
care costs. RESULTS: A total of 1164 patients (mean age: 39.8 years, 61.7% female) 
were observed for 2.6 years on average. Projected per-patient health care costs in G4 
European countries, excluding Topiramate, would be signiﬁcantly higher during 
generic-use periods (adjusted cost differences per person-year: a706 to a815, p  0.001 
for all comparisons) compared to brand-use periods. Assuming mandatory generic 
substitution for all patients, predicted system-wide increases in total adjusted health 
care costs would range from 3.5% (UK) to 24.4% (France) one year after generic 
entry. Increases in non-Topiramate health care costs (13.7% to 18.1%) would more 
than offset savings in incremental Topiramate brand costs (6.3% to 13.8%) in 
France, Italy, and the UK. CONCLUSIONS: The generic entry of Topiramate in 
Europe is projected to be associated with higher health care costs, representing a 
trade-off between reduced generic drug expenditures and increased health care 
costs.
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OBJECTIVES: investigated the impact of generic substitution of the branded antiepi-
leptic drug (AED) Topiramate (Topamax®) on medical service utilization and costs 
for patients with epilepsy in Germany. METHODS: Retrospective health claims from 
Québec’s provincial health plan (RAMQ) between January 2006 and September 2008 
were analyzed. Patients with epilepsy (ICD-9: 345, 780.3 or 780.39) and q2 topira-
mate (Topamax®) dispensings were selected. Patient-level health care utilization and 
costs in Canada were calculated during mutually-exclusive periods of brand versus 
generic use of topiramate. Annualized Canadian health care costs were converted into 
a German setting (a2007/person-year) by applying purchasing power parities, service-
use ratios and exchange rates. Using market-level sales, branded and generic topira-
mate utilization were forecasted for 12 months following expected generic entry 
(September 2009-September 2010) using autoregressive and panel-data regression 
models. Non-parametric bootstrap procedure was used to determine statistical signiﬁ-
cance for the cost measures. Budgetary consequences for sick funds, individual and 
private payers were assessed. RESULTS: After adjusting for covariates, periods of 
generic topiramate use were associated with signiﬁcant increases in pharmacy dispens-
ings (other AEDs: 6%, non-AEDs: 31%, p  0.001), a 17% increase in hospitaliza-
tions (p  0.015), and 21% longer lengths of hospital stays (p  0.001). Converted 
per-patient health care costs excluding topiramate were estimated to be signiﬁcantly 
higher for generic relative to brand periods in Germany (adjusted cost difference per 
person-year [95% CI]: a710 [a149–a1283]; p  0.001). Assuming mandatory generic 
substitution for all patients, predicted system-wide increase in total adjusted health 
care costs would be 23.2% one year after generic entry. This impact would be evenly 
distributed among payers. CONCLUSIONS: Generic entry of topiramate in Germany 
would represent a trade-off between reduced generic drug expenditures and increased 
health care costs due to higher AED and non-AED spending, as well as increased 
hospitalizations and outpatient visits. Increased total cost is expected to outweigh the 
beneﬁt of reduced drug costs.
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OBJECTIVES: In addition to medical treatment, deep brain stimulation (DBS) has 
become an alternative therapeutical option in advanced Parkinson’s disease, especially 
for motor complications such as dyskinesias or motor ﬂuctuations. High initial costs 
of surgery and subsequent time-consuming maintenance procedures may be traded off 
by long-term gains in quality of life (HrQoL) compared to conventional medication 
treatment. This leads to the question whether DBS is cost effective compared to best 
medical treatment. METHODS: We present a lifetime Markov model for Parkinson’s 
disease, comparing deep brain stimulation vs. best medical treatment and estimating 
the impact on health-related quality of life. HrQoL was measured by the EQ-5D and 
cost from the societal perspective of Germany. Both were discounted with 3% p.a.. 
Data on DBS efﬁcacy and adverse events were taken from clinical studies and pub-
lished reports or meta-analyses. Key assumptions on the surgery procedure and its 
durability, its impact on cost and HrQoL, mortality, prevalence of motor complica-
tions as well as stage transition probabilities and the discount rate were investigated 
by one- and two-way sensitivity analyses. RESULTS: The incremental cost effective-
ness ratio (ICER) for DBS was a42,183 per QALY gained. Incremental DBS costs were 
due to cost for surgery and subsequent battery change. HrQoL was improved and 
motor complications were reduced. The following variables had most impact in sen-
sitivity analyses: utility improvement under DBS, drug and surgery cost, progression 
rates, and discount rate leading to varying ICERs between 20,064 and a58,147/QALY 
(the latter due to extreme and unlikely parameter combinations). CONCLUSIONS: 
Based on our decision analysis using current guidelines, DBS is likely to be cost-
 effective compared with other well-accepted health care technologies. We suggest to 
adopt DBS for patients with high drug cost or severe motor complications.
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OBJECTIVES: The objective was to demonstrate the cost-effectiveness of a new 
absorbable hydrogel used in craniotomies compared to the option “do nothing” in 
France. METHODS: A Markov model was fed with clinical data from Grotenhuis 
and al. (Surg. Neurol. 2005;64:490–3) and with cost data from the French cost data-
base (2006 data based on DRG (GHM) 01C04V craniotomy without complication 
and 01C04W craniotomy with complication). The model was run with three stages 
(T0: date of surgery; T1: 1-month follow-up; T2: 3-month follow-up) and three states 
